UnitedHealth Group revises its 2025 performance outlook amidst rising healthcare costs, especially within Medicare Advantage services, as Q1 2025 sees a notable revenue growth to $109.6 billion.
Discover why UnitedHealth Group's stock experienced its largest decline in over 20 years following Q1 earnings that fell short of Wall Street expectations. Learn more about the factors influencing its financial performance and future outlook.
A detailed overview of the ongoing legal challenge by NYC municipal retirees to retain traditional Medicare supplemental insurance against a proposed switch to Medicare Advantage.
Exploring the challenges and strategies for U.S. healthcare finance leaders in the transition to value-based care with the rise of Medicare Advantage and Medicaid Managed Care.
The Common Sense Caucus supports NYC retirees in a legal battle against transitioning to a Medicare Advantage plan, highlighting a pivotal case for municipal commitment to retiree healthcare.
U.S. lawmakers are requesting a GAO investigation into Medicare Advantage organizations' business strategies, concerning adherence to federal health care spending requirements.
A case involving UnitedHealth Group and allegations of improper Medicare reimbursements highlights compliance and regulatory challenges in U.S. health insurance.
President Trump's executive order delays Medicare drug price negotiations, favoring pharmaceutical companies and potentially increasing drug costs for the public.
President Trump's latest executive order modifies the Medicare Drug Price Negotiation Program, aligning the treatment of small molecule drugs with biologics and aiming to reduce drug prices.
President Trump signed an executive order to lower Medicare drug prices by enhancing drug price negotiations, increasing market transparency, and targeting anti-competitive behaviors.
